Skip to main content
UCB's Global Corporate Website
Healthcare Professionals
Patients
Investor Relations
Careers
instagram
facebook
twitter
youtube
linkedin
rss
Search Results
Main navigation
UCB - Inspired by patients. Driven by science.
Chercher
Our Company
About Us
Management
Sustainability
Health of the Planet
Conserving water
Health of the planet - CO2e
Reducing waste
Partnering
Suppliers
Become our supplier
Our Team
Requisition to Pay Process
Funding
Funding
Grants
Investigator-Initiated Studies
Disclosure Of Payments
Disclosure of payments to Healthcare Professionals
Belgium
Denmark
Finland
Hungary
Ireland
Italy
Netherlands
Norway
Other countries
Romania
Sweden
Ukraine
Responsible Procurement
Digital Business Transformation
Ethical Business Practices
Our positions
Disease Areas
Disease areas
Epilepsy New
Our Science
Overview
Drug discovery
Capabilities
R&D locations
Clinical studies
Innovation is
Pipeline
Clinical Studies
Overview
Clinical studies at UCB: How are medicines made and tested?
Current studies
Clinical studies index
Rozanolixizumab (Rystiggo®)
Zilucoplan (Zilbrysq®)
General information
Data Transparency Policy
Access to Patient-Level Clinical Study Data
Plain Language Summaries of research results
Peer-Reviewed Publications
Registration and Results Reporting on Public Registries
Study Reports and Synopses
Our Products
Products
Bimzelx®
Briviact®
Cimzia® - Ankylosing spondylitis (AS)
Cimzia® - Axial spondyloarthritis (axSpA)
Cimzia® - Crohn's disease
Cimzia® - Plaque psoriasis (PsO)
Cimzia® - Psoriatic arthritis (PsA)
Cimzia® - Rheumatoid arthritis (RA)
Evenity®
Fintepla®
Keppra®
Nayzilam
Neupro® - Parkinson's disease
Neupro® - Restless Legs Syndrome
RYSTIGGO
Vimpat®
Newsroom
Overview
Press releases
Form
Our stories
Resources
Contact
HCP
HCP Overview
Women of childbearing age
Immune to the impossible
Podcasts
Rheumacensus
Patients
Overview
Life stories
Women of Childbearing Age
Investors
Overview
UCB equity story
UCB financials
Full year financial results
Half-year financial results
UCB Governance
UCB shareholders
Share repurchase program
Shareholders meeting 2016
Shareholders meeting 2018
Shareholders meeting 2019
Shareholders meeting 2020
ESG overview
Download center
EMTN Notes documents
Eurobond 2013 documents
Eurobond 2021 - documents
Exchange offer documents
IR team
Careers
Applying to UCB
Go to global site
Search
Country Navigator
Listen
Search results
Please use the searchbox on top of the site.
Your search yielded no results.
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
Our Company
About us
Management
Sustainability
Health of the Planet
Partnering
Suppliers
Funding
Disclosure of payments
Digital Business Transformation
Ethical Business Practices
Our positions
Disease Areas
Disease Areas
Our Science
Drug discovery
Capabilities
R&D locations
Clinical Studies
Innovation is
Pipeline
UCB Worldwide
Select country
Search
Our Products
Products
Newsroom
Overview
Press Releases
Our stories
Resources
Contact
Patients
Patients
Life stories
Women of Childbearing Age
Investors
Overview
UCB equity story
UCB financials
UCB Governance
UCB shareholders
ESG overview
Download center
IR team
HCP
HCP Overview
Women of childbearing age
Immune to the impossible
Clinical Studies
Overview
Current studies
Clinical studies index
General information
Data Transparency Policy
instagram
facebook
twitter
youtube
linkedin
rss
